التفاصيل البيبلوغرافية
| العنوان: |
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database. |
| المؤلفون: |
Brown, J. R., Eichorst, B., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., Ma, H., Tedeschi, A. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p459-461, 3p |
| مصطلحات موضوعية: |
DATABASES, COUGH, CLINICAL trials, BRUTON tyrosine kinase |
| مستخلص: |
B Introduction: b Bruton tyrosine kinase inhibitors (BTKi) block B-cell receptor pathway signaling, leading to growth inhibition and cell death in malignant B-cells. Here, we characterized the overall safety/tolerability of zanu and compared it with ibr in patients (pts) with B-cell malignancies using the zanu clinical safety database. Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder